USPTO serial 50097981
OSLUNVAY
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- SAMSON, LEANNA JOYCE C
- Law office
- TMO LAW OFFICE 138
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with OSLUNVAY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Indianapolis, IN, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John R. Rudolph
Lilly Corporate CenterIndianapolis, IN 46285United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, asthma, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, cancer, cardiovascular disease, central nervous system diseases and disorders, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hearing loss, heart failure, infectious diseases, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, obstructive sleep apnea, opioid use disorder, osteoarthritis, pain, Parkinson's disease, psoriasis, psoriatic arthritis, pulmonary diseases, retinal disease, rheumatoid arthritis, tobacco use disorder, ulcerative colitis, vascular diseases and vision loss; pharmaceutical preparations for weight management; vaccines for human use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 23, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 9, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 9, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 9, 2026 | NWAP | NEW APPLICATION ENTERED | — |